About Aspect Biosystems
Aspect Biosystems is a company based in Vancouver (Canada) founded in 2013 by Simon Beyer, Tamer Mohamed, Sam Wadsworth, and Konrad Walus.. Aspect Biosystems has raised $138.68 million across 5 funding rounds from investors including Novo Nordisk, Innovate BC and Canadian Space Agency. Aspect Biosystems offers products and services including Bioprinting Technology Platform. Aspect Biosystems operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, Collplant, ROKIT Healthcare and Triastek, among others.
- Headquarter Vancouver, Canada
- Founders Simon Beyer, Tamer Mohamed, Sam Wadsworth, Konrad Walus
-
Sectors
Technology
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aspect Biosystems Ltd.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$138.68 M (USD)
in 5 rounds
-
Latest Funding Round
$115 M (USD), Series B
Jan 08, 2025
-
Investors
Novo Nordisk
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aspect Biosystems
Aspect Biosystems offers a comprehensive portfolio of products and services, including Bioprinting Technology Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI-powered system for creating implantable tissues to treat diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of Aspect Biosystems
Aspect Biosystems has successfully raised a total of $138.68M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $115 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $115.0M
- First Round First Round
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series B - Aspect Biosystems | Valuation | Dimension | |
| Jan, 2020 | Amount | Series A - Aspect Biosystems | Valuation | Radical Ventures | |
| Nov, 2018 | Amount | Series A - Aspect Biosystems | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aspect Biosystems
Aspect Biosystems has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Novo Nordisk, Innovate BC and Canadian Space Agency. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Dimension is focused on investments at the intersection of technology and life sciences.
|
Founded Year | Domain | Location | |
|
Early-stage sector agnostic VC firm investing primarily in the US and Canada
|
Founded Year | Domain | Location | |
|
Companies developing T1D products are funded through venture philanthropy.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aspect Biosystems
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aspect Biosystems
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aspect Biosystems Comparisons
Competitors of Aspect Biosystems
Aspect Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, Collplant, ROKIT Healthcare and Triastek, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Desktop bioprinter for genes and proteins production is developed.
|
|
| domain | founded_year | HQ Location |
3D bioprinters and bioinks are developed for research applications.
|
|
| domain | founded_year | HQ Location |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| domain | founded_year | HQ Location |
4D bio-printer solutions for tissue regeneration are provided.
|
|
| domain | founded_year | HQ Location |
Provider of 3D printing pharmaceutical technology platform for drug design
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aspect Biosystems
Frequently Asked Questions about Aspect Biosystems
When was Aspect Biosystems founded?
Aspect Biosystems was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Where is Aspect Biosystems located?
Aspect Biosystems is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Who is the current CEO of Aspect Biosystems?
Tamer Mohamed is the current CEO of Aspect Biosystems. They have also founded this company.
Is Aspect Biosystems a funded company?
Aspect Biosystems is a funded company, having raised a total of $138.68M across 5 funding rounds to date. The company's 1st funding round was a Series A of $2.7M, raised on Sep 18, 2017.
What does Aspect Biosystems do?
Aspect Biosystems was founded in 2013 in Vancouver, Canada. Bioprinting technology and tissue therapeutics are developed within the regenerative medicine sector. The platform is integrated with computational design, therapeutic cells, and biomaterials to produce implantable tissues. These tissues are designed to replace, repair, or supplement biological functions, particularly for metabolic and endocrine diseases. Collaborations with other organizations are maintained to advance operations.
Who are the top competitors of Aspect Biosystems?
Aspect Biosystems's top competitors include Nuclera Nucleics, Allevi and Collplant.
What products or services does Aspect Biosystems offer?
Aspect Biosystems offers Bioprinting Technology Platform.
Who are Aspect Biosystems's investors?
Aspect Biosystems has 12 investors. Key investors include Novo Nordisk, Innovate BC, Canadian Space Agency, Dimension, and Pallasite Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.